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Heart failure with preserved ejection fraction (HFpEF) is a condition associated with low 
quality of life, high morbidity and mortality. It constitutes a diagnostic challenge and there is 
little evidence of effective treatments. In spite of its high prevalence and the fact that many 
(17-36%) of these patients are managed in Primary Care (PC) most of the studies on the 
condition were performed in Hospital Care (HC). 
Aims 
 The aim of this thesis was to describe HFpEF in PC, its characteristics, comorbidities and 
mortality as well as further prognostic and diagnostic difficulties and potential underdiagnosis 
 Methods 
The initial three studies were based on the Swedish quality registry for Heart Failure (HF) 
patients (SwedeHF). Patients without echocardiographic results (16%) were excluded. A total 
of 1802 patients from PC and 7852 from HC, all with an Ejection Fraction (EF) ≥ 40% were 
studied to identify comorbidities, risk factors and outcomes, and to compare PC- with HC-
patients in the first study.  
The second study analyzed the prognostic value of N-terminal Brain Natriuretic Peptide 
(NT-proBNP) in HFpEF-patients managed in PC. 924 patients; 360 patients with EF 40-
49%, Heart Failure with Midrange Ejection Fraction, (HFmrEF) and 564 patients with 
EF≥50% (HFpEF). 
 The third study identified gender differences and was based on the 1802 patients from Study 
1, divided into HFmrEF and HFpEF.  
The fourth study was performed in Gustavsbergs PC centre. Ninetysix patients that had 
contacted the General Practitioner (GP) unit for one of the three common HF- symptoms 
breathlessness, tiredness or ankle swelling were included to find potential underdiagnosis and 
to evaluate an internet-based self-test for HF. 
Results 
HFpEF patients managed in PC were older and the majority were women, compared with 
patients managed in HC. Only 2.8% had no comorbidity and all-cause mortality after 1 year 
was 7.8%. Smoking, Chronic Obstructive Pulmonary Disease (COPD) Diabetes mellitus 
(DM), age and heart rate were shown to be independent risk factors for mortality in PC. 
Echocardiographc examinations are often missing. In matched controls there were more 
RAS-antagonists and betablockers prescribed in HC. Study I. 
There was a clear association between levels of NT-proBNP and mortality, but only on a 
group level. Numerous variables were associated with increased NT-proBNP and further 
independently with mortality. Study II. 
Men had higher age-adjusted mortality than women. In women with HFpEF more than half 
of the cases had another cause of death than cardiovascular diseases. The dominating causes 
of death were malignant diseases and respiratory diseases but altogether 13 different causes 
were identified. Study III. 
There was an underdiagnosis of HFpEF of 21%, all in women. We also found an acceptable 
accuracy of an internet-based self-test for HF. Study IV. 
Conclusion 
Patients with HFpEF in PC constitutes a heterogenous group with high age and many 
comorbidities that may interfere with the pathophysiology of HF and irrespectively affect 
both morbidity and mortality. The patients are older (mean 78 y.), the proportion of women is 
higher (46.7% vs 36.3 %) and they have other independent risk factors than those managed in 
HC. A single evidence-based treatment of HFpEF-patients is not available. The results of this 
thesis suggest that HFpEF-patients in PC have an age-related multi-organ damage with great 
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 Probably, the first case of Heart Failure (HF) is Nebiri, the Egyptian, who lived 3500 years 
ago and whose remnants were found in the Queens Valley. Histologic examination of the 
lungs showed findings of suspect pulmonary edema. Various descriptions of cases that could 
be HFwas then found throughout the antique period, but it was not until the English physician 
William Harvey in 1628 described the construction of the circulatory system that we began to 
understand the basis of hemodynamics. Initial therapies included bloodletting, with or 
without leeches. Another English physician, William Withering, introduced digitalis as 
therapy in 1785, and in 1918 Henry Starling, physician from Cambridge, contributed to the 
understanding of heart physiology. Still, in the middle of the 20th century, HF was mainly 
treated with inactivity, rest and fluid restriction. On the pharmacological side there were no 
more alternatives than diuretics and digitalis. In 1967 south-african surgeon Christiaan 
Barnard performed the first heart transplantation, and in the middle of the 1980s there was 
growing knowledge that HF is to be considered as a disease of the neuroendocrine system. 
The “Consensus 1” – study was presented in 1987 and could for the first time show the 
benefits of blockade of the RAS system, followed later on with studies showing the benefits 
of BB therapy. During the 1990s HF was more and more considered as being a syndrome, 
instead of merely a disease, and it was also by this time we began to realize the complexity of 
HFpEF. We now started to understand that this condition is the response of the heart to other 
strains and diseases, such as diabetes and hypertension, and not like in HFrEF primarily a 
damage to the heart. In 1995 the European Society of Cardiology (ESC) launched the first 
guidelines for HF-management and from the period around the millennium shift and further 







Table 1. Important HF studies 
Study Year Comments 
Consensus 1987 First study to show improved 
survival with an ACEi 
Solvd 1991 Survival benefit from the 
ACE-inhibitor enalapril 
Rales 1999 Survival benefit from 
spironolactone 
Cibis-2 1999 Survival benefit from the 
betablocker bisoprolol 
Merit-HF 1999 Survival benefit from the 
betablocker metoprolol 
Copernicus 2001 Survival benefit from the 
alfa-  and betablocker 
carvedilol 
Val-HeFT 2002 Survival benefit from the 
angiotensinreceptor blocker 
valsartan 
Charm 2003 Survival benefit from the 
angiotensinreceptor blocker 
candesartan 
Care-HF 2005 Survival benefit from cardiac 
resynchronization therapy 
Shift 2010 Survival benefit from 
ivabradine 







HF is to be understood as a condition where the heart, due to structural or functional 
impairment, is unable to deliever oxygenated blood in the required amount that meets the 
needs of the tissues of the body. It is a clinical syndrome, involving an active neuroendocrine 
system, and is in the latest ESC guidelines classified as either Heart Failure with reduced 
Ejection Fraction (HFrEF), Heart Failure with mid range Ejection Fraction (HFmrEF) or 
Heart Failure with preserved Ejection Fraction (HFpEF). All three categories require typical 
symptoms  and clinical signs for the diagnosis and are thereafter classified due to Ejection 
Fraction (EF): HFrEF< 40 %, HFmrEF 40-49% and HFpEF ≥50%. Furthermore, HFmrEF 
and HFpEF, on new onset, must have elevated levels of natriuretic peptides and at least one 
more of either findings of structural heart disease or diastolic dysfunction. [1] Once the 
diagnosis is confirmed the patient’s functional capacity according to the New York heart 
Association (NYHA) are also estimated, constituting a base for treatment guidelines. 
Table 2. Typical symptoms of HF according to ESC 
Breathlessness 
Orthopnoea 
Paroxysmal nocturnal dyspnea 
Reduced exercise tolerance 










Table 3. Definition, at the time of diagnosis, of heart failure with reduced (HFrEF), mid-
range (HFmrEF) and preserved ejection fraction (HFpEF) according to ESC guidelines 2016. 
Type 
of HF 
HFrEF HFmrEF HFpEF 
 
Criteria 
Symptoms and signs Symptoms and signs Symptoms and signs 
EF<40% EF 40-49% EF≥50% 
 
1. Elevated levels of 
natriuretic peptides 







1 Elevated levels of 
natriuretic peptides 














No limitation of physical activity. Ordinary physical activity does not cause undue 
fatigue, palpitation, dyspnea (shortness of breath).  
II  
Slight limitation of physical activity. Comfortable at rest. Ordinary physical 
activity results in fatigue, palpitation, dyspnea (shortness of breath).  
III  
Marked limitation of physical activity. Comfortable at rest. Less than ordinary 
activity causes fatigue, palpitation, or dyspnea.  
IV  
Unable to carry on any physical activity without discomfort. Symptoms of heart 





HF is a common condition and must be considered as a scourge. Various studies estimate the 
prevalence to be around 2% but rising with age to around 10% at the age of 80 years. Yearly 
incidence has been estimated to be between 4 and 7 cases per 1000 inhabitants, the higher 
figure among men. [2-7] Incidence has been declining during the last decades, more so for 
women, while prevalence in various studies has remained unchanged or decreased, especially 
among women.[2-5] On the other hand more patients survive myocardial infarctions and may 
be better treated for Hypertension, (HT) which might lead to increasing incidence in the 
future. [8, 9] It has further been shown that there is a decrease in mortality among both men 
and women. [3]  
 
1.1.1.4 Etiology 
HF is caused in most of the cases (70%) of either Ischemic Heart Disease (IHD) or HT [2, 
6, 10, 11] the former representing an injured myocardium and the latter abnormal loading 
conditions.  However, many patients will have several different etiologies, both 
cardiovascular and non-cardiovascular, that cooperate to cause HF. Most important other 
causes are valvular diseases, cardiomyopathies, toxic damage, metabolic derangements, 
inflammatory damage, infiltration diseases, genetic abnormalitites, anemia, sepsis, renal 
failure, and arrythmias. 
 
1.1.1.5   Comorbidity 
Comorbidities are common among HF patients and are associated with increased morbidity 
and mortality in both HFrEF and HFpEF. [12]Many patients have several comorbidities that 
together may contribute to a worse prognosis and in many studies it has also been shown that 
non-cardiac comorbidities substantially play a role for negative outcome. [13-15] Reasons for 
this may be a direct stress from the comorbidity on the failing heart but potentially also 
missed diagnosis and delayed treatment of HF. Predictors for worse outcome are also other 
factors (among others age, anemia and elektrolyte changes) that often may co-variate with 
several comorbidities. [14] 
Several studies have shown that Chronic Obstructive Pulmonary Disease (COPD), Diabetes 
Mellitus (DM), anemia and obesity is more common among HFpEF patients than HFrEF 




1.1.1.6  Prognosis 
Mortality in patients with HF is high but varies with etiology and functional capacity 
according to NYHA-classification. Only 50% of the patients with the lowest functional 
capacity (NYHA IV) are alive after one year. [2, 11, 22] Mortality is highest for hospitalized 
patients [22-24] and is generally comparable with various forms of cancer. [10, 25] One-year 
mortality in the Swedish Heart Failure Registry for hospitalized patients is approximately 
20%, regardless level of EF. [26]  
Mortality has remained essentially unchanged or slightly decreased over the past years after a 
decline in the late 20th century and in spite of new therapies and management [3, 5, 27, 28] 
but it has been shown that mortality is declining more for men than for women. [28] Most 
studies have been performed on hospitalized patients, both with HfrEF and HfpEF, [8, 9, 11, 
17, 18, 20, 29] where women have been shown to have a lower mortality, [2, 22, 30, 31] and 
that the mortality is lower both in cardiovascular deaths and non-cardiovascular deaths. 
Women have also been shown to die to a lesser distinct from cardiovascular deaths than 
men.[32]  The gender difference in mortality is however modified by different conditions (i.e. 
atrial fibrillation, kidney disease and ischemic heart disease). [33] 
Mortality for hospitalized HFpEF patients is high and in many studies comparable to 
mortality for HFrEF patients. [18, 21, 29, 34] The mortality is modified by various conditions 
and comorbidities, [12-14, 16, 35] and it has further been shown that patients with HFpEF die 
to a larger distinct from non-cardiovascular diseases than patients with HFrEF even though 
the main cause of death is cardiovascular diseases. [13, 21, 34, 36, 37]  Similar pattern has 
been shown for HFmrEF although IHD is more common among HFmrEF than HfpEF. [38, 
39] The most common other causes of death are respiratory diseases and malignant tumors. 
[37, 40-42] 
Mortality for HF patients in general, and for HFpEF patients especially, managed in PC, has 
not been extensively studied but some studies indicate a lower mortality compared with 







1.1.2 Significance of heart failure 
1.1.2.1 Significance to patients 
Patients with HF have high mortality, well comparable with cancer, [10, 25] and due to high 
morbidity and many comorbidities [16, 29] a low quality of life, lower than that of most other 
diseases. [46, 47] 
 
1.1.2.2 Significance to community 
HF is one of the most common reasons for need of hospital care, and among persons older 
than 65 years, in many studies the single most common reason. A vast number of hospital 
beds and treatment days are required at cardiology-, internal medicine- and geriatric clinics. 
[5, 17, 48-52]  
The cost for HF treatment in Sweden is substantial and there have been several attempts to 
calculate the total burden. Various studies have ended up with estimations between 3 and 7 
billion Swedish kronor yearly for HF treatment, depending on which type of costs and 
patients that are included in the study.[49-51]  The main cost driving factor is hospital care. 
The frequency of readmissions for HF within 90 days may be as high as 30-40 % [17, 29, 48, 
51] .  Improved knowledge, information, follow-up and treatment at nurse based outpatient 
clinics may decrease the readmission rate with up to 50%, leading to substantial reduce of 
health-care costs.[23, 48, 51, 53-55]  There is a large potential for improvements of HF care, 
not least since many studies furthermore have shown that many patients are not only treated 
deficiently according to guidelines but also poorly diagnosed. [6, 19, 24, 56-61]   
 
Physiology of heart failure 
1.1.2.3 Anatomy 
The heart weighs between 200 to 425 grams and is a little larger than the size of a fist. Each 
day, the average heart beats 100.000 times. 
The heart is located between the lungs in the middle of the chest, surrounded by the 
pericardium. The heart has four chambers; two atria, right and left, and two ventricles, right 
and left. Between the two atria and ventricles is a wall of muscle, called the septum.Veins 
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from the blood system deliever deoxygenated blood to the the right atrium from where the 
right ventricle is filled. The right ventricle pumps the deoxygenated blood to the lungs and 
oxygenated blood will then return to the left atrium. After filling of the left ventricle, the 
blood will finally be pumped in to the systemic vessels.  
There are four valves regulating blood flow through the heart; the tricuspid valve between the 
right atrium and right ventricle, the pulmonary between the right ventricle and the pulmonary 
arteries, the mitral valve between the left atrium and the left ventricle and the aortic valve 
between the left ventricle and the aorta. 
Electrical impulses cause the heart to contract. The electrical impulse starts in the sinoatrial 
node at the top of the right atrium and travels through the atrioventricular node and then via 
the atrioventricular bundle and the bundle branches to the ventricles, causing them to 
contract.  
The right and left coronary arteries run along the surface of the heart and provide oxygenated 
blood to the heart muscle. 
 
1.1.2.4 The healthy heart 
The coordinated process of a heart beat, named cardiac circle, consists of two phases; a 
contraction phase (“systole”) and a relaxation phase (“diastole”). The right and left atria 
and ventricles synchronize during systole and diastole. During the cardiac circle, the 
pressure in the cardiac chambers increases or falls and this will cause valve opening or 
closure. This, in turn, will regulate blood flow between the chambers as the blood flows 
from a high-pressure area to a low pressure-area. Multiple noninvasive evaluations have 
been utilized in order to stratify heart function. However, the “golden standard” for 
measuring the heart function is heart catheterization. 
At the first part of the cardiac circle, (atrial systole and ventricular filling), when the 
pressure is low, circulating blood will passively fill the atria on both sides. The 
atrioventricular valves opens and blood moves into the ventricles. The atria therafter 
depolarizes, contracts and residual blood is pushed into the ventricles. This is the last part 
of the diastolic phase and the amount of blood in the ventricles at this phase is named end 
diastolic volume (EDV). The atria will now relax as the electrical impulse is transmitted to 
the ventricles that will depolarize. As the ventricles start to contract (ventricular systole), 
 
 15 
the pressure in the ventricles increases and at the point where the pressure exceeds the 
pressure within the arteries, the pulmonary and aortic valves will open, and the blood will 
be pumped into the vessels. In the next phase (isovolumetric relaxation) the ventricles relax, 
the pressure in the ventricles drops causing a backflow in the pulmonary and aortic trunks 
and the pulmonary and aortic valves close. The amount of blood remaining in the ventricles 
after the contraction is referred to as end systolic volume (ESD). While the ventricles have 
been contracting, the atria have been relaxing and are now ready to be filled again for the 
next cardiac circle.  
The efficacy of the heart function can be measured as cardiac output (CO), the amount of 
blood pumped out by the heart in one minute. CO is calculated as the stroke volume (SV) 
multiplied with the heart rate. SV, in turn, is calculated as the difference beween EDV and 
ESV. CO varies in respond to metabolic needs, for example with exercise, and where a 
normal CO at rest is around 5-6 liter /minute it may increase to around 15-25 liter/minute at 
exercise. In a healthy heart the tonus in the vessels in the body adapts to SV in a well 
regulated metabolic and neurohormonal balance. Factors as the sympatic and parasympatic 
nerve system and various metabolic substances influence this reaction and the heart rate. 
The SV is dependant on the preload, meaning the filling of the returning blood from the 
circulation, which in turn determines CO. Increased pressure in the ventricles results in 
increased contractility. In a healthy heart the preload and contractility of the heart are 
positively correlated up to a certain point, known as the Frank-Starling law. The 
contractility of the heart is affected by various hormones and chemicals. If they stimulate 
contractility, they are said to have a positive inotropic effect, and if they decrease 
contractility, they are said to have a negative inotropic effect. 
1.1.2.5 The viscious circle of heart failure  
When the heart, due to various diseases and disturbances in systolic and/or diastolic function, 
is unable to produce an adequate SV and thus deliever the required amount of oxygen to the 
body, compensatory mechanisms, mainly from the the RAS- system and the sympathetic 
nervous system, will be activated. These systems are old compensatory regulators for loss of 
volume due to bleedings, infections, and thirst and are, as such, effective to maintain CO via 
increased heart rate, vasoconstriction, sodium and water retention and increased muscle 
strength. However, in a diseased heart these mechanisms will further strain the situation by 
increasing the peripheral resistance. The body is unable to differ this situation from that of a 
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bleeding and further activation of the RAS- and sympathetic nervous system will occur in an 


















































Figure 1. The vicious circle of HF 
1.1.2.6 Systolic dysfunction 
Systolic dysfunction is in a way the easiest to understand, and also the easiest to measure. 
Consquently many studies have been performed on the condition leading to multiple effective 
treatments. When the heart muscle, due to for example a myocardial infarction, is damaged 
the ventricular contraction will be impaired and as a result SV will be decreased. The most 
Heart failure 
























common method to measure systolic function in clinical praxis is by defining Left Ventricular 
Ejection Fraction (LVEF or often EF), either with echocardiography (most common) or 
magnetic resonance imaging. EF is calculated as the difference between EDV and ESV 
(=SV), divided with EDV and expressed in percent where EF over 55% is considered normal. 
In the latest ESC guidelines, however, HF with EF <40% is classified as HFrEF, HF with EF 
40-50% as HFmrEF and HF with EF ≥50% as HFpEF. [1] 
 
1.1.2.7 Diastolic dysfunction 
Diastolic dysfunction is somewhat more difficult to understand and to measure, compared 
with systolic dysfunction, and to do this properly it is important to be familiar with the 
different phases of diastole. There are four phases: the isovolumetric relaxation time (IVRT), 
the early rapid filling, the diastasis and the late filling as a result of atrial contraction. IVRT is 
the period between the closure of the aortic valve and the opening of the mitral valve during 
which time the pressure in the heart is falling. When the pressure in the ventricle is below that 
in the atrium the mitral valve will open, and the early rapid filling occurs. This can be 
measured with doppler-echocardiography as the E-wave or early diastolic phase and is 
normally caused both by the suction from the ventricle and the pressure in the atrium. The 
speed of the E-wave is normally higher in younger individuals due to better relaxation and 
suction in the ventricle. The phase after the E-wave is the diastasis in which the difference in 
pressure between the atrium and the ventricle is around zero and almost no flow occurs. The 
last phase of diastole is the atrial component in which the contraction of the atrium causes the 
A-wave, measured with doppler-echocardiography. Normally the E/A-ratio is 1.5-2.0 in 
younger individuals and between 0.7-1-0 in persons over 70 years of age. 
Figure 2. The normal diastolic phase 
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There are different methods to measure diastolic function in clinical praxis. All are based on 
and compared with cardiac catheterization which is “golden standard”. 
Evaluation of the mitral inflow with doppler-echocardiography. Measures the E/A-ratio, the 
DT (E-wave deceleration time = DT = time for declining of the flow velocity in early 
diastole) and the IVRT (length of the isovolumetric relaxation time = IVRT = time to start of 
ventricles filling after relaxation). 
 
Tissue Doppler measuring of the motion of the mitral annulus. Similar to conventional 
doppler-echocardiography the method will show an E- and A-wave, here named e´ and a´, 
representing early and late diastolic filling. Tissue Doppler is also useful for measuring time 
intervals. In a situation of diastolic dysfunction / impaired relaxation, e´ will be lower, and at 
the same time the E-wave increases with elevated filling pressures. The E/e´ ratio will 
increase and an E/e´ratio >14 is highly suggestive of elevated filling pressures. 
Pulmonary vein flow. This technique enables measuring the blood flow in the pulmonary vein 
which, in a situation of diastolic dysfunction, will be shifted from systole to diastole.  
Color Doppler M-mode. Studies early diastolic inflow into the left ventricle. 
Indirect signs of diastolic dysfunction. Atrial enlargement. Left ventricular hypertrophy. 
Dilated pulmonary veins. Raised pulmonary artery pressures. Tricuspid regurgitation. 
Pulmonary hypertension. 
 
Diastolic dysfunction can be divided into four different grades: 
Grade I (impaired relaxation): The normal filling of the ventricle is disturbed due to 
ventricle stiffness and the E-wave will decrease. More blood is left in the atrium and the A-
wave will be larger. As the E wave velocity is reduced the E/A is reversal (ratio < 1.0). The 
left atrial pressures are normal. The E/e’ ratio measured by tissue Doppler is normal. This 
can also be a normal finding and occurs in many individuals by the age of 60 years. 
Grade II (pseudonormal): As the diastolic dysfunction progresses the pressure in the 
atrium will rise and the E-wave increase. The E/A ratio will return to the range of 0.8 to 1.5, 
looking very much like normal diastolic function and therefore named pseudonormal 
dysfunction.This is however pathological. Pseudonormal diastolic dysfunction may be 
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distinguished from normal function by the pulmonary vein flow, the presence of structural 
heart disease such as left atrial enlargement, left ventricular hypertrophy or systolic 
dysfunction and further by an elevated E/e’ ratio (>14). Valsalva will also distinguish 
pseudonormal from normal as the E/A ratio will be < 1 during the maneuvre. 
Grade III (reversible restrictive): In this phase with further increased pressure in the atrium 
the gradient between the atrium and the ventricle will increase.The flow into the ventricle 
starts earlier and terminates quickly. Thus, the E/A ratio is > 2.0, the deceleration time is < 
160 ms, and the E/e’ ratio is elevated.Valsalva maneuvre may change the pattern to that of 
pseudonormal dysfunction. 
Grade IV (fixed restrictive): This is the most severe form of distolic dysfunction, indicating 
a poor prognosis and very elevated left atrial pressures. The E/A ratio is > 2.0, the 
deceleration time is short and the E/e’ ratio is elevated. The major difference distinguishing 
grade III from grade IV diastolic dysfunction by echocardiography is the lack of E/A 
reversal with the Valsalva maneuver.  
The diagnosis of HfpEF by echocardiography is a difficult task and it has been pointed out 
in the ESC guidelines that the diagnosis requires either evidence of diastolic dysfunction or 
findings of structural heart disease.  
Understanding the mechanisms of diastolic dysfunction will help us to understand HFpEF 
since this condition is associated with aging and remodeling due to hypertension. Further, we 
begin to realize why HFpEF is more common among women. It has been shown that women 
have more remodeling and less dilatation than men [9] . The age-related stiffness of the heart 
is more pronounced among women which may be one explanation to the greater 





Figure 3. Diastolic dysfunction. Pressure-Volume curve 
 
1.1.3 Diagnostics of heart failure 
1.1.3.1 Symptoms and signs 
There are numerous symptoms and clinical signs associated with HF, often classified with the 
Framingham criteria. [2] However, symptoms and clinical signs have generally low 
sensitivity (varying between 10 and 90% with the highest sensitivity for breathlessness on 
exertion) and specificity (varying between 70 and 99% with the highest specificity for 
breathlessness at rest) for diagnosing HF and are unsufficient alone for the purpose. [7, 63-
66] At best, symptoms and clinical signs may help the clinician to catch attention for the 
diagnosis and lead to futher proper examination.[64]   
 
1.1.3.2 Differential diagnosis 
Mentionable conditions that may resemble HF include IHD, lung diseases (preferably 
COPD), arythmias, anemia, venous insufficiency, kidney disease, obesity and thyroid 
diseases. Given the low sensitivity and specificity of signs and symptoms mentioned above, 
further diagnostic procedures are essential. Many studies have shown that patients may be 
underdiagnosed or misdiagnosed. [6, 7, 19, 24, 57-61] There is also evidence of 
overdiagnosis in up to 30% of the cases [67] , potentially leading to wrong treatment and 
damage to the patients, and a poor use of recommended diagnostic procedures. [24, 57, 59-
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61, 68] Not least in PC may this be a problem, considering the extensive disease panorama 
that meets the PC clinician every day.  




Electrocardiogram is a valuable, cheap and harmless tool in the diagnostic procedures of HF. 
It is efficient to rule out HF, [69] and furthermore adds information upon the cause of the 
disease. In the latest ESC guidelines for all types of HF it is recommended as an important 
diagnostic step, [1] together with analysis of natriuretic peptides. 
 
1.1.3.4 Natriuretic peptides 
Natriuretic peptides (NPs) (Atrial natriuretic peptide (ANP), Brain natriuretic peptide (BNP) 
and C-type natriuretic peptide (CNP) are synthesized by cardiovascular, brain and renal 
tissues.[70] NPs provide vasodilation and natriuresis and acts as a compensatory mechanism 
against cardiac overload in a HF situation. In that way, they counteract the activated RAS-
system and other neurohormonal systems.[71] They are regulators of blood pressure, water 
and salt homeostasis and also markers of cardiac dysfunction.[72, 73] Elevated levels of NPs 
correlate with the severity of HF and high levels of NPs also indicate a worse prognosis for 
both readmission and mortality.[74, 75] This has been shown both for HFrEF and HFpEF. 
[76, 77] Most studies have been performed on hospitalized patients but there are some data 
from PC. [59, 78, 79] 
Low values of NPs (particularly BNP and N-Terminal proBNP (NT-proBNP)) are efficient to 
rule-out suspected HF [80, 81], due to a high negative predicitive value, and are now 
recommended in international guidelines as an important diagnostic step together with an 
ECG. The combined use of ECG and NPs has a negative predicitive value of 0.94-0.98 to 
exclude HF.[1, 69, 81-86] Important to remember for the clinician, however, is that there are 
numerous other conditions (renal failure, pulmonary embolus, pulmonary hypertension) 
causing elevated NPs, hence the varying specificity for HF diagnosis between 75 and 94% 
and the importance of further diagnostic procedures. [87, 88]  
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Although measuring NPs is a simple and not too costly tool to help the clinician to diagnose 
suspected HF, it has been shown that the method is poorly used [61] but recently, however, 
there are reports of increased use in PC.[89] 
NPs has been well established in the diagnostic procedure as well as prognostic markers.  
Consequently, there has also been hopes that they may support management and treatment of 
HF. However, several randomized clinical trials (RCTs) have shown that NP-guided 
treatment has given conflicting results and it is uncertain whether this would lead to a better 
outcome than simply optimizing treatment according to guidelines.[90, 91]  
 
1.1.3.5 Chest X-ray 
Although chest x-ray is often performed in the diagnostic procedures to find HF, its 
contribution to the HF diagnosis itself is poor and the importance of x-ray is merely to 
establish other differential diagnosis such as lung diseases. 
 
1.1.3.6 Echocardiography 
The most important diagnostic procedure for HF in clinical praxis is echocardiography which 
not only is essential for the diagnosis but also provides information about type of HF, severity 
and sometimes underlying mechanisms. [92, 93] In spite of its importance many studies have 
pointed at a low use of the method. Hobbs et al showed that echocardiography was only used 
in 32% of HF-patients in PC.[57]  In HC, Cleland could show somewhat better, but still not 
satisfactory, results (66%) [94] as well as Valk (73%) [67] In PC, other studies results are 
even worse with a use of echocardiography ranging from around 30% [59, 60] down to as 
low as 8.5%. [44] The combined use of NPs and echocardiography has further been shown to 
have a low degree of utilization. (9%) [68, 95] 
Heart-catheterization is considered “golden standard”, however not possible to perform in 
clinical praxis. 
1.1.4 Treatment of heart failure   
 Treatment of heart failure with reduced ejection fraction 
There are multiple evidence-based and established therapies for HFrEF, many of which are 
introduced in the late 20th century. Common factor for these therapies is the perception that 
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what is essential in HFrEF is a neuro-hormonal dysfunction. The most important 
pharmacological categories are: 
-Angiotensin Converting Enzyme inhibitors (ACEi) 
-Angiotensin Receptor Blockers (ARB) 
-Betablockers (BB) 
-Mineral Receptor Antagonists (MRA) 
All these pharmacological treatments have been able to show positive effects on morbidity, 
mortality and quality of life in large RCTs [96-105] If there are no contra-indications they 
should always be considered for managing HFrEF and are well established in international 
guidelines. [1] 
Beyond these established base-treatments, patients with HFrEF may also benefit from 
treatment with diuretics, Angiotensin Receptor–Neprilysin Inhibitors (ARNI), iron-infusion 
and digitalis and further, on certain indications, Cardiac Resynchronization Therapy (CRT), 
Implantable Cardiac Defibrillator (ICD), Left Ventricular Assistant Device (LVAD) and 
heart transplantation. 
There is also substantial evidence that nurse-led HF receptions with patient education can 
improve functional capacity, adherence to guidelines therapy and reduce readmission rates. 
[53, 55] as well as that physical exercise reduces mortality and hospitalization [106] 
Some patients may also benefit from procedures directed to the ethiological cause of their 
HF, i.e. Coronary Artery Bypass Graft surgery (CABG), Percutaneous Coronary Intervention 
(PCI), valvular surgery or heart transplantation. 
The above mentioned therapies are all established and recommended in international 
guidelines but, in spite of that, there are many studies indicating lacking or poor use in a real-
world setting.[57, 60, 89, 107] 
Further, it has also been shown that women receive less treatment according to guidelines, 




1.1.4.1 Treatment of heart failure with preserved ejection fraction 
There have been many attempts to find an evidence-based reliable pharmacological therapy 
for HFpEF but no RCT has yet managed to show significant effects similar to those for 
HFrEF. Some effects have been shown on hospitalization and diastolic function but still not 
on mortality. [109, 110] Some observational studies indicate positive effects of RAS- and 
beta-blockade [111, 112] and it has been shown that physical activity may have positive 
effects on physical capacity and quality of life and further that weight reduction may be 
beneficial among obese patients. [113, 114] Saltreduction has been associated with reduced 
30 days mortality [115] and a structured nurse-led programme with improved lipid profile, 
functional capacity, quality of life and weight loss.[45] 
 Most important, given the large proportions of comorbidities among HFpEF patients, and the 
contribution of these comorbidities to mortality, not least non-cardiac mortality, is to 
adequately treat these comorbidities and other conditions that may affect the HFpEF 
patient.[116, 117]  
1.1.5 Heart failure with preserved ejection fraction 
A large group of HF patients is the one with preserved ejection fraction, HFpEF. This 
condition is as common as HFrEF but in contrast there is no evidence-based treatment. 
Morbidity and mortality is comparable with that of HFrEF when hospitalized and there is still 
lack of knowledge about the development and progress of the disease.[118-120]   Many 
studies have shown that the mortality for HFpEF patients is equal to, or slightly lower than, 
the mortality for HFrEF patients with a one-year mortality of 20-25% for those requiring 
hospital care. [8, 17, 18, 21, 29, 34] Even the rehospitalization frequency is comparable [23] 
Diagnostics of HFpEF is more challenging than in HFrEF and there is probably substantial 
underdiagnostics, especially since many variables may be normal at rest but pathological at 
exercise. [121] The patients normally do not have a dilated left ventricle but instead more 
often left ventricular hypertrophy and/or a dilated left atrium as a sign of increased filling 
pressure. The insights that HFpEF is a complex syndrome where systolic, chronotrop, 
vascular, endothelial and peripheral factores contribute and where a disturbed active 
relaxation and a passive stiffness is present are becoming increasingly obvious [121] Most 
patients have signs of disturbed diastolic function which also is considered the main 
mechanism of the condition.[9, 62]  The patients are older, more often women and with more 
hypertension and atrial fibrillation than HFrEF patients but more seldom ischemic heart 
disease.[7, 9, 11, 17-21, 122]  It is a heterogenous group with different ethiologies and 
pathopfysiological abnormalities and it has further been suggested that, compared with 
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HFrEF patients, hospitalization and mortality is more often caused by non-cardiac conditions. 
[34, 54, 109]  
There are differences between women and men where women are older and more 
overweight, have a higher NYHA-class, more often treated with diuretics, have less ischemic 
heart disease but more hospitalizations than men. [30] In contrast, men have more IHD, AF 
and DM, are more often current or previous smokers compared with women and have higher 
age-adjusted all-cause mortality than women.[22, 30-32]  
No treatment has yet been shown to convincingly have effect on morbidity and mortality in 
this group. Since the patients often are elderly, with many symptoms and a low quality of life, 
much of the care must be concentrated on managing the due diseases and relieve 
symptoms.[116, 117] Physical activity has been shown to improve the physical condition and 
quality of life and, among obese patients, weight loss may improve the prognosis.[113, 114] 
If the patients have fluid excess they may benefit from salt- and fluid restriction. 
Comorbidities have a greater impact on functional class and physical capacity among HFpEF 
patients and hospitalization is more often caused by non-cardiac conditions than for HFrEF 
patients.[12-14, 21, 34, 54, 123, 124]  
 The diagnose of HFpEF is difficult and the condition may be undetected, not least in primary 
care that manages patients with many diagnoses and often diffused symptoms.[7, 18, 44, 57, 
58, 95, 125]  
 
 
1.1.6 Heart failure in primary care 
Many HF- patients are managed in PC, often in cooperation with HC but also mainly in PC, 
in various studies between 17 and 36%.[3, 15]  
Patients managed in PC are older with a higher proportion of women and a lower mortality 
than those managed in HC.[29] There are relatively fewer patients having HFrEF and, 
although the mortality is lower than in HC, it has been shown that the quality of life is poor 
among both HFrEF and HFpEF patients.[29, 126, 127] Comorbidities are common and for 
example COPD coexists in up to 25% and may often be underdiagnosed.[15, 67]  There are 
some studies on diagnostics and treatment of HF in PC, generally showing a need for 
improvement.[57, 60, 67, 86, 94, 107]  Early intervention and team-based management are 
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important [128, 129] but it has been shown that follow-up and adherence to guidelines is 
poorer in PC than in HC.[57, 60, 89, 94, 107]  
Most importantly, there are a limited amount of studies on HFpEF in PC. Some studies have 
shown that patients in PC are older with a higher proportion of women and a better functional 
capacity according to NYHA-classification, compared with HC.[17, 44, 68, 122, 126] 
Overweight, diabetes, low hemoglobin are strongly associated with HFpEF whereas male 
gender is strongly associated with HFrEF.[122]  It has been shown that HFpEF is more 
common than HFrEF in PC [126]  and that risk factors for developing HFpEF is obesity, 
hypertension, diabetes and kidney disease.[122]   Many studies have described a high 
frequency of comorbidities but have not consequently distinguished PC from HC.[12-14, 16, 
17, 54, 123]  It has though been shown the importance of these comorbidities, not least for 
COPD and diabetes.[15, 125]  Further, it has been described that the use of diagnostic tools, 
such as ECG, NPs and echocardiography, is poor which markedly diminishes the possibility 
to adequately determine type of HF and design the right treatment.[44, 95]  Consequently, 
many studies point at underdiagnostics of the condition.[57, 60, 61, 66, 68, 94]  Correct 
identification of the type of HF is important not only for the patient, with potentially wrong, 
harmful and expensive treatment, but also for future research and development.[44, 95]  
Concerning treatment of HFpEF pharmacologically there are few studies in PC but it has 
been shown that a structured nurse-led management can improve quality of life, body weight, 
emotional status, functional capacity and lipid profile.[45]  
There are also a limited number of studies on mortality for HFpEF patients in PC but it has 
been shown that men have a higher risk of mortality and hospitalization together, compared 
to women.[44]  
1.1.7 Quality registries 
National quality registries have been used in Sweden for more than forty years and are a 
system of quality tools designed to develop and improve care management.[4]  All registries 
contain information about the patients’ diagnosis, treatment and results. There are today 
around one hundred different registries, sponsored by the government and producing 
continuous information to the health care system.  
The HF quality registry (SwedeHF) was founded in 2003 by Ulf Dahlström, Magnus Edner 
and Åsa Jonsson and it serves particiant units with: 
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-Continous information about carachteristics, diagnostics, treatment, quality of life and 
functional capacity for their HF patients. 
-Continous information on-line to concerning their own data compared with the national data. 
-Information on adherence to guidelines for every unit. 
-Yearly reports on mortality, morbidity, diagnostics, medical treatment, functional capacity 
and quality of life to every unit and compared with the national data. 
-Research on the HF data. 
When creating the registry a national group of experts developed a protocol with indicators of 
quality of life, background, diagnostics, treatment and follow-up of the HF-patients in the 
registry and the registry has been the base for many scientific articles.[26]  
1.2 AIMS 
1.2.1 Gaps of knowledge 
Despite the fact that HFpEF is a common disease, often managed in PC, there are substantial 
gaps of knowledge. We lack information of; 
-The characteristics of the HFpEF population in PC 
-The mortality of the HFpEF population in PC 
-Comorbidities in HFpEF patients in PC  




1.2.2 Main aim  
The main aim of this thesis is to describe characteristics, comorbidities, challenging 
diagnostic, prognosis and potential underdiagnosis of the HFpEF population in PC. 
-The characteristics of the HFpEF population in PC vs HC. Study I.  
-Prognostic factors. Study I.  
-The utility of NT- proBNP. Study II.  
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-Gender differences among HFpEF patients in PC. Study III. 
-The mortality of the HFpEF population in PC and causes of death. Study III. 
-Potential underdiagnosis. Study IV. 
 
 
1.2.3 Secondary aim 
The secondary aim of this thesis is to describe and evaluate an internet-based diagnostic tool 




1.3 MATERIALS AND METHODS 
1.3.1 Material (I) 
In the first study we used data from SwedeHF. SwedeHF is one of the world’s largest HF 
registries and was created in 2003. It is an Internet-based registry designed to help the 
participating units to improve the management of their patients, having unrestricted access to 
their own data, but also to form a base for research on HF. Both hospitals and PC centres in 
Sweden participate in the registry but it is not mandatory even though there has been 
recommendations from the Swedish Board of Health and Wellfare. Approximately 80 
variables including demography, concomitant diseases, diagnostics, medication and 
laboratory data are prospectively entered into the registry. Registration is performed either at 
discharge from hospital or at an out-patient visit at hospital or in PC. Patients are informed 
that their hospital or PC centre is participating in the registry and that it is approved by a 
multisite ethic committee. Patients are allowed to opt out.The database is built to handle 
sensitive information and each participating unit can only have access to their own data, but 
after application to the Steering Committee, data from the entire registry can be obtained for 
research purposes. 
Data from a prospectively collected material in a registry form a solid base for observational 
studies but is not ideal for studying the effect of treatment where a RCT is the optimal choice. 
However, in a RCT many patients are excluded due to high age, certain comorbidities and 
 
30 
other factors, whereas in a registry all patients remain, regardless of these factors. The 
registry therefore constitute a research base that is more representative to real.  
Furthermore, the size of the registry, the participation of both hospitals and PC centres and 
the possibility to merge the registry with other national registries expands the utility of the 
registry. 
We used data in SwedeHF recorded between First of September 2001 and 15th of May 2014 
for this study and the database was merged with the Swedish population registry and the 
Swedish patient registry of hospitalization. By 2014 Sweden had 1156 PC units and 67 
hospitals out of which 116 PC units and 67 hospitals participated in the registry. The registry 
contained 59075 patients in 2014, 6579 from PC and 52496 from HC. Since we wanted 
comparable data from both PC and HC we only included patients recorded at an out-patient 
visit. We also wanted to be sure that the patients had HF (inclusion criteria in the registry is 
clinician-judged HF), and further whether their EF was equal to or above 40%, and therefore 
we excluded patients without information about echocardiography (1041 = 15.8% in PC and 
5938 = 11.3% in HC). Finally, we excluded patients with an EF<40 % and patients with EF≥ 
40% but hospitalized. The total number of patients remaining in the study was then 1802 
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1.3.2 Method (I) 
We used both descriptive and analytical methods to analyze the cohort in the first study. We 
constructed baseline tables for PC and HC patients respectively and for all patients in the 
database but also for the subgroups with EF 40-49% and with EF ≥50%.  
We calculated and chartered mortality for the whole group, and for EF 40-49% and EF≥ 
50%, using the Kaplan-Meier method and we constructed tables for 1, 3 and 5 years mortality 
rates for the same three groups. Tables for the above mentioned mortality ranges were also 
contructed for patients with no comorbidity in PC or HC and for those with any comorbidity. 
Multivariate regression analyses were performed for time dependent different variables, 
calculating hazard ratios (HR) with 95-% CI for mortality. 
We wanted comparable groups when analyzing medication, and since patients with higher 
age, renal function impairment and low blood pressure might be referred to hospital before 
RAS-antagonists or betablockers are prescribed. We matched patients in the overall cohort 
for age (±1 year), gender (same), systolic blood pressure (>110 mm Hg) and eGFR-class 
(same). After matching, 1499 patients remained in each group. Baseline tables were 




1.3.3 Material (II) 
For the second study we used the same data-base from Swede-HF as in study one. After  
exclusion of patients not suitable for our work, that population consisted of 1802 PC patients 
and 7852 HC patients, all with an EF of more than or equal to 40%.(fig.3) 
In the second study we aimed to assess the prognostic significance of plasma NT-proBNP in 
patients with HFmrEF and HFpEF in PC. We therefore excluded patients in HC and those in 
PC without a measurement of NT-proBNP registered. The data-base for this study consisted 
after that of 924 patients. All patients were divided into two groups: 360 patients with EF 40-
49% (HFmrEF) and 564 patients with EF≥50% (HFpEF). 
  
1.3.4 Method (II) 
We constructed baseline tables for the two EF-groups separately using descriptive statistics.  
 
 33 
All-cause mortality was calculated and chartered for the two EF-groups using the Kaplan-
Meier method (KM). KM curves for quartiles of NT-proBNP and mortality were constructed 
for the whole cohort as well as for HFmrEF and HFpEF separately and we also calculated 1-, 
3- and 5-years mortality rates for the two EF-groups. 
We performed univariate and multivariate regression analysis for mortality to calculate 
Hazard Ratios (HR) for the different variables in the data-base in order to analyze whether 
NT-proBNP was an independent risk factor for mortality. 
Variables that were associated with increased NT-proBNP were analyzed with same method 
as for those that were associated with mortality. Both EF-groups were analyzed with this 
method. 
Finally, we identified comorbidities in the two EF-groups separately and which comorbidities 
that were associated with all-cause mortality after a primary univariate and secondary 
multivariate Cox proportion hazard regression analysis. 
 
 
1.3.5 Material (III) 
In the third study we aimed to study gender differences in patients with either HFmrEF or 
HFpEF, managed in PC. We therefore used the entire PC data-base of 1802 patients, 
described in Study 1(fig nr 3). Patients were divided into four groups, women with EF 40-
49% (HFmrEF, n=283), men with EF 40-49% (HFmrEF, n=470), women with EF≥50% 
(HFpEF, n=559) and men with EF≥50% (HFpEF, n=490) 
1.3.6 Method (III) 
We constructed baseline tables for the whole cohort of 1802 patients and for the four EF-
groups separately.  
Mortality among women and men was analyzed with the KM method. We primarily 
constructed curves for crude mortality and secondarly, since age highly affects mortality, age-
adjusted KM-curves. 
Mortality difference between women and men was further analyzed with multivariate Cox 
proportion hazard regression analysis taking into account age, COPD, IHD, AD, valvular 
disease, DM, HT, NYHA-class, Hb-level and kidney dysfunction. 
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Further, using logistic regression analysis, we calculated the one-year mortality rate for the 
different age-groups <60, 60-69, 70-79. 80-89 and >90 years for both women and men. 
Univariate regression analysis for various comorbidities and their association with mortality 
were performed for women and men in the four EF-groups and the result presented as a 
Forest Plot. 
Causes of death were analyzed for women and men in the whole cohort and in the four EF-
groups separately. Groups were presented as in the International Classification of Diseases 
(ICD) registry. Differences were analyzed with the Chi-square test. The result was presented 
with pie charts. 
 
1.3.7 Material (IV) 
In the fourth study we aimed to validate an internet-based questionary to detect HF (described 
below) and further to investigate potential underdiagnosis of HF at a PC unit. We actively 
scanned medical records at the PC centre of Gustavsberg, (Stockholm, Sweden) for patients 
that had searched for one or more of the three HF symptoms breathlessness, tiredness or 
ankle swelling during the period January to March 2019. Those that already had an 
established HF diagnosis were excluded as well as those that at the following doctor’s visit 
were properly examined for HF. Patients that remained were contacted and asked if they were 
willing to enter the study. The study was improved by ethnic committee and all patients 
received written information and signed Informed Consent. 
1.3.7.1 Internetbased questionary 
A questionary for potential HF was constructed in care of a HF quality project (4D HF 
project 2012-2018) in Stockholm, Sweden and presented at an internet platform. The 
questionary contained nine questions regarding age and gender, hereditary factors, 
etiology, symptoms and signs. Specifically, these issues were further divided into; 
breathlessness at exertion, breathlessness at rest, weight gain, ankle swelling, previous 
diseases, cytostatic treatment and hereditary factors. Various points were given to the 
answers and an automatic reply with one of the three following alternatives; HF unlikely 
(<3 points), HF possible (3 to 8.5 points but not answer yes on breathlessness at rest) , HF 
likely (9 to 12.5 points or 3 to 9.5 points and answer yes on breathlessness at rest) was 




1.3.8 Method (IV) 
Patients that agreed to participate in the study, and had signed informed consent, were 
summoned to an appointment with a doctor. Medical history and status was uptaken 
whereafter patients were asked to fulfill the internet-based questionary for HF and to estimate 
their quality of life according to the EQ5D scale. ECG and blood test for NT-proBNP was 
performed and all patients were referred to spirometry and echocardiography.  
The complete results were then analyzed first separately by an experienced general practioner 
(BE) respectively a cardiologist (HP) and secondary as a common consensus and following 
the diagnostic criteria from ESC. Points of judgement were symptoms, clinical signs 
according to the Framingham criteria, ECG, NT-proBNP values, echocardiographic findings 
of either systolic or diastolic dysfunction and finally a consensus on whether the patients had 
HF or not and, if so, which type of HF defined as either HFrEF, HFmrEF or HFpEF. ECG 
was classified as normal or pathological and a cut off value of >125 ng/l for NTproBNP was 
used. 
The result of the consensus assessment was then used as a “golden standard” when evaluating 
the internet-based questionary’s reliability to detect HF or not. Sensitivity, specificity, 
positive predictive value, negative predictive value, likelihood ratio for positive and negative 
results were calculated for the test. 
All patients were contacted when the study was finished and informed of their results. Those that 
received a new diagnose of HF were given a personal appointment and follow-up at the GP unit. 
1.3.9 Statistics 
Descriptive statistics were used and results presented as numbers and percentages or means 
with standard deviations (SD). Categorical variables were analyzed using the chi-square test 
and continuous variables using the student t-test. Levels considered statistically significant 
were a p-value<0.05. All p-values and 95% confidence intervals (CI) were 2-sided. (Study I, 
II and III) Univariate regression analyses were used to calculate hazard ratios for mortality for 
different variables. Variables with a p-value of 0.1 or below in that analysis were then entered 
into a multivariate logistic regression analysis to determine Hazard Ratio (HR) with 95% CI 
for mortality. (Study I, II and II) The result was presented as a Forest plot. (Study I and II) 
HR for medication was finally also analyzed for the matched cohort. (Study I)  






All studies were approved by a multisite or local ethic committee. 
1.4 RESULTS 
1.4.1 Study 1, paper I 
1.4.1.1 Characteristics 
Patients managed in PC were significantly older than those managed in HC, 77.5 vs 70.3 
years (p<0.0001) and there were more patients with an EF≥50% (26.1% vs 13.4%, 
p<0.0001). In the PC cohort the proportion of women was greater than in HC. (46.7% vs 
36.3%, p<0.0001). When dividing the overall cohort into EF 40-49% and EF≥50% there were 
considerably more women in the PC cohort with EF≥50% (53.3% vs 44.0%, p<0.0001). 
Functional capacity according to NYHA classification was often missing (45.4% missing in 
PC and 46.1% in HC) but, when reported, patients managed in PC had a better functional 
class (72.2% in NYHA I or II vs 69.1% in HC, p<0.01). This difference was most 
pronounced in the group with EF≥50%. 
Patients in PC had higher heart rate, systolic blood pressure (mean 134 mm Hg vs 129, 
p<0.0001), diastolic blood pressure (mean 75.1 mm Hg vs 73.7, p<0.0001) and more renal 
dysfunction (48.1% eGFR< 60 ml/kg/min vs 41.5%, p<0.0001). 
1.4.1.2 Comorbidities 
There was a high frequency of comorbidities in both the PC and the HC cohort. In PC only 
2.8% had no comorbidity vs 7.7% in HC. Figures for comorbidity in the two different EF-
cohorts were similar in both PC and HC. Patients in PC had significantly more AF (53.0% vs 
47.2%, p<0.0001), HT (67.0% vs 48.9%, p<0.0001), IHD (57.8% vs 32.7%, p<0.0001) and 
COPD (24.5% vs 15.2%, p<0.0001).   
1.4.1.3 Mortality 
Mortality after 1 year was 7.8% in the PC cohort and 7.0% in the HC cohort, corresponding 
figures after 3 years was 22.8% in the PC cohort and 17.0% in the HC cohort and after 5 
years 28.9% vs 23.0%. Mean follow-up time was 1151 days in PC and 1286 days in HC after 
which mortality was 31.5% in PC vs 27.8% in HC. When comparing the subgroups with EF 
40-49% vs EF≥50% the results were consistent.  
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After multivariate logistic regression analysis smoking, COPD, DM, age and heart rate were 
shown to be independent risk factors for mortality in PC and in HC valvular disease, kidney 
dysfunction, IHD, COPD, AF, low diastolic blood pressure, high heart rate and age. 
 
1.4.1.4 Medication 
Medication was only compared in the matched cohorts. There were more prescribed RAS-
antagonists in the HC cohort (83.7% in PC vs 87.6% in HC, p<0.05) and betablockers in HC 
(74.2% in PC vs 85.7% in HC, p<0.0001). In HC the combination of RAS-antagonists and 
betablockers was more used (63.8% in PC vs 75.2% in HC, p<0.0001). There was no 
difference concerning MRAs.  
1.4.2 Study 2, paper II 
1.4.2.1 Characteristics 
There were more women (54% vs 39%, p<0.0001) and higher age (mean age 78.2 vs 76.3, 
p<0.01) in the HFpEF group compared to the HFmrEF group. More interventional 
procedures (Coronary artery bypass grafting or Percutaneous coronary intervention) were 
performed among HFmrEF patients whereas HFpEF patients more frequently had sinus-
rhythm on the ECG and normal chest x-ray. ACE-inhibitors, betablockers and statins were all 
prescribed more within the HFmrEF group. There was also a tendency, however not 
statistically significant, to more patients with IHD in the HFmrEF-group.  
There was no significant difference between the two EF-groups concerning mortality 
(p=0.26) and the 1-year mortality was 8.1% for HFmrEF-patients and 7.3% for HFpEF-
patients. Corresponding figures for 3- and 5 years mortality were 23.9% vs 23.6% and 44.7% 
vs 37.2%. 
1.4.2.2 The prognostic value of NT-proBNP 
There was a clear association between levels of NT-proBNP and mortality where the patients 
that died after 1 year had the highest levels of NT-proBNP. However, the SD- values were 
huge. 
After Kaplan-Meier analysis, there was a significant association between NT-proBNP 
quartiles and mortality the highest quartile having the highest mortality (p<0.0001).  (mean 




As for the whole cohort patients that belonged to the group with the highest NT-proBNP 
quartile had the highest mortality. (HR 1.96 (95% CI 1.60-2.39, p<0.0001 in a univariate 
analysis and HR 1.83 (95% CI 1.38-2.44, p<0.0001) after multivariate Cox proportion hazard 
regression analysis). 
1.4.2.4 HFpEF 
The same pattern as for HFmrEF patients were observed in the HFpEF group. Patients with 
the highest NT-proBNP quartile had the highest mortality (HR 1.72 (95 % CI 1.49-1.98) p-
value < 0.0001, in a univariate analysis and HR 1.48 (CI 1.16-1.90) p-value <0.0001 after 
multivariate Cox proportion hazard regression analysis). 
 
1.4.2.5 Variables associated with increased NT-proBNP 
In the HFmrEF group numerous variables were associated with increased NT-proBNP in a 
univariate analysis (age, NYHA-classification, hemoglobin level, systolic blood pressure, 
diastolic blood pressure and body weight) but following multivariate Cox proportion hazard 
regression analysis only age and low hemoglobin level remained statistically significantly 
associated with increased NT-proBNP. 
For HFpEF patients there was also an association between numerous variables and increased 
NT-proBNP in a univariate analysis (age, NYHA-classification, hemoglobin level, diastolic 
blood pressure, body weight, valvular disease, AF, DM and kidney dysfunction) but after 
multivariate Cox proportion hazard regression analysis only valvular disease and low body 
weight remained statistically significantly associated with increased NT-proBNP. 
 
1.4.2.6 Comorbidities affecting all-cause mortality 
Frequency of comorbidities were high in both EF-groups (97% in HFmrEF and 98% in 
HFpEF), the most common comorbidity being HT (64% among HFmrEF patients and 70% 
among HFpEF patients) followed by AF (more than 50% in both groups). Combinations of 
comorbidities were common and among HFpEF patients the combination of COPD and HT 
was twice as common as among HFmrEF patients. 
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Numerous comorbidities were associated with all-cause mortality in a univariate analysis 
among HFmrEF patients age, low body weight, low diastolic blood pressure, low hemoglobin 
level, low creatinine clearance class and high NYHA class and among HFpEF patients age, 
low body weight, low diastolic blood pressure, low hemoglobin level, creatinine clearance 
class, COPD, valvular disease and NYHA class) but after multivariate Cox proportional 
hazard regression analysis only NYHA class remained highly significant with all-cause 
mortality in the HFmrEF group (HR 2.09 (CI 1.37-3.18), ) and age (HR 1.07 (CI 1.02-1.12)), 
low body weight (HR 0.98 (CI 0.96-1.00)), COPD (HR 2.13 (CI 1.21-3.74) and NYHA class 
(HR 1.67 (CI 1.08-2.59) in the HFpEF group.  
1.4.3 Study 3, paper III 
1.4.3.1 Baseline characteristics and gender differences in the whole cohort 
Women were older (mean age 78.7 vs 76.4, p<0-0001), had more valvular disease (26.5% vs 
21.4%, p<0.05), higher systolic blood pressure (mean 136.1 vs 133.1, p<0.01), lower 
hemoglobin level (mean 130.6 vs 136.8, p<0.0001) and more kidney dysfunction (mean 
eGFR 58.4 vs 65.7, p<0.0001) whereas men were more smokers (38.3% vs 60.8%, 
p<0.0001), had more IHD (34.9% vs 48.7%, p<0.0001), AF (49.6% vs 56.1%, p<0.01) and 
DM (17.2% vs 24.5%, p<0.01). Men also more frequently had gone through cardiovascular 
revascularization procedures (11.7% vs 29.0%, p<0.0001). 
1.4.3.2 HFmrEF vs HFpEF 
Age increased with EF-group among both women and men but women were still older than 
men in both groups. The proportion of women increased from 37.6% in the HFmrEF-group 
to 53.3% in the HFpEF-group and the prevalence of IHD decreased in both women and men. 
Men still were more smokers and had more IHD in both groups but the difference concerning 
AF and DM was only seen in the HFpEF-group. In both groups women had more kidney 
dysfunction and lower hemoglobin levels. 
1.4.3.3 Medical drugs in HF-patients with EF equal to or above 40% 
Women in the HFpEF-group were more often treated with digitalis (17% vs 13%, p<0.05) 
while men in the whole cohort more often were prescribed statins (37.3% vs 52.1%, p< 
0.0001), aspirin (40.8% vs 47.9%, p<0.01) and ACE-inhibitors (51.5% vs 60.2%, p<0.0001). 
There was a low prescription rate of anticoagulantia in the whole cohort among both women 
and men (37.9% vs 41.2%), in spite of AF frequency of 49.6% vs 56.1%. 
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1.4.3.4 Mortality and gender differences in HFpEF-patients  
 
When assessed with the Kaplan-Meier method there was no difference in crude mortality 
between women and men. However, when the analysis was age-adjusted, men had highly 
statistically significantly higher mortality (p<0001). After adjusting for COPD, IHD, AF, 
valvular disease, DM, HT, age, NYHA-class, Hb-level and kidney dysfunction this difference 
remained highly statistically significant.  
1.4.3.5 Mortality and gender associated co-morbidities 
Comorbidities that were associated with higher mortality were in the HFmrEF-group among 
women valvular disease (p <0.05), AF (p <0.05) and kidney dysfunction (p <0.001) and 
among men kidney dysfunction (p<0.0001) and Hb level (p<0.0001). In the HFpEF-group 
the corresponding associations were among women COPD (p<0.01) and among men valvular 
disease (p <0.01), COPD (p <0.05) and kidney dysfunction (p<0.001). 
1.4.3.6 Causes of death and differences by gender and ejection fraction 
In the whole cohort there was a significant difference between women and men concerning 
malignant tumors as cause of death, where the figures were 8.6% among women and 15.4% 
among men (p<0.05). The major cause of death was however in both groups cardiovascular 
diseases (includes myocardial infarction, HF and stroke), (55.6% among women and 59.8% 
among men (n.s)), followed by respiratory diseases (15.2% among women and 11.3% among 
men (n.s)). These three causes of death were dominating in the cohort but there were 11 more 
groups of death-causes, and more than 90% of the patients had one or more comorbidities 
that potentially could influence the cause of death.   
In the HFmrEF-group there was no significant difference between women and men and the 
three dominating causes of death were the same. In the HFpEF group cardiovascular diseases 
were still dominating as cause of death but decreasing among women (65.0% in the HFmrEF 
group vs 45.1% in the HFpEF-group (p <0.01), however not statistically significantly 
different compared with men (45.1 % vs 55.4% (p=0.06). Malignant tumors were more 




1.4.4 Study 4, paper IV 
We found 96 patients that had contacted the GP unit for one of the three symptoms 
breathlessness, tiredness or ankle swelling during the examined period of time. After 
excluding those that already had a diagnosis of HF (n=18) and those that were properly 
investigated for HF (n=45) 33 patients remained and were contacted. 24 responded positively, 
signed informed consent and entered the study. Mean age was 70.5 years, and the range was 
52 to 85 years, 11 were women and 13 men. The underlying diagnosis was IHD in 3 of the 
cases, HT in 16 and COPD in 9 of the cases. 5 of the patients had none of these diagnoses. 
Symptoms were breathlessness in 18 of the cases, tiredness in 18 and ankle swelling in 6 of 
the cases (some patients had more than one of the symptoms) The EQ5D score ranged from 
30 to 99 and the NT-proBNP value from 28 to 1090.Pathological ECG was found in 7 of the 
cases, spirometry with findings of COPD in 6 cases and asthma in 3 cases. 
1.4.4.1 Validation of the internet-based questionary 
As stated below, 5 of the patients proved to have HFpEF and in these cases the test showed 
possible or likely HF in 4 of the cases and HF unlikely in 1 of the cases. Within the 19 
patients that were considered not having HF the test indicated HF unlikely in 14 of the cases 
but HF possible or likely in 5 of the cases. 
Based on these results for the test we calculated a sensitivity of 80% and a specificity of 74%. 
The negative predictive value for the test was 93% and the positive predictive value 44%. 
Likelihood ratio for positive results was 3.08 and likelihood ratio for negative reuslts 0.27. 
 
1.4.4.2 Underdiagnosis of HF 
The result of the echocardiographic examination was normal in 19 of the cases. We found no 
patient with disturbed systolic function but 5 with disturbed diastolic dysfunction. All these 
patients were also considered having HFpEF after GP and cardiologist concensus taking into 
account symptoms, signs, ECG, NT-proBNP and echocardiography and following the 
diagnostic criteria of ESC. 4 of the patients were women and 1 a man. Age ranged from 67 to 
84 years and mean-age was 75.8. NT-proBNP ranged from 87 to 743. Symptoms were 
tiredness within all 5 and breathlessness within 3 of the patients. 18 of the 96 original patients 
had known HF and we found another 5 with unknown HF, all with HF and preserved ejection 
fraction (HFpEF), among the 24 that joined the study. Based on this, we estimated under-
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diagnosis of HF (HFpEF) in a population with HF symptoms that was not properly examined 
to 21%.  
1.5 DISCUSSION 
General comments 
HFpEF patients are to a large extent (17-36%) managed in PC. They have low quality of life, 
high morbidity and the costs for care are substantial. In spite of this there is limited 
knowledge on HFpEF in PC and a need for further research. 
In the field of medical research, quality registries provide a unique possibility to obtain and 
analyze large data bases. Sweden’s personal number system further gives opportunities to 
link data from a registry to other national registries, thus creating even more information 
upon the different cohorts of patients. The SwedeHF is one of the largest heart failure 
registries in the world, both in the number of patients and the amount of variables, and has 
been the base for many scientific publications. Collecting corresponding data on HFpEF in 
PC without a quality registry would be very difficult and time-consuming. 
Of obvious importance when analyzing data is that the diagnosis of the disease is correct. 
When discussing HFpEF this is of extra interest since the diagnosis is depending on well- 
performed echocardiographic examinations with specific diagnostic criteria. We 
compensated for the lack of echocardiographic examinations by excluding patients without 
information upon the examination (16 % in the PC registry). Thus, we only had patients 
with knowledge of EF left. Still the registry does not contain information about the other 
requiered information concerning diastolic function and structural changes, wherefore the 
diagnosis is based on clinical judgement and EF. Patients in SwedeHF, and in our studies, 
are also prospectively registered from 2001, and criteria of diastolic HF have endeed 
changed since we started our study. SwedeHF also lack information concerng some 
important coconmittent diseases as MT and psychologic disorders. 
Finally, studying HFpEF patients without any other disease would perhaps be optimal to 
really identify the unique character of the disease. However, such a scenario is only existing 
in the imagination. The real-world panorama is, as this thesis shows, quite opposite. 
 
Characteristics 
Patients with HFpEF managed in PC are characterized by higher age and a larger proportion 
of women than those managed in HC. Further there are more patients with an EF≥50% and 
this is most pronounced among women. Furthermore, patients in PC have higher blood 
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pressure and more kidney dysfunction than those managed in HC, perhaps reflecting that 
patients in PC suffer from multi-organ damage and that HFpEF in this cohort is merly a part 
of a more complex and pathological aging. In contrast to HFrEF patients, where IHD is 
dominating as an obvious, and easy to identify, cause of HF, patients with HFpEF in PC 
stands out as a noticeably heterogenous group. Many of their various diseases affect each 
other, for example HF and kidney disease, HF and COPD, HF and DM, HF and malignant 
tumors, and in the individual case it may be difficult to identify which disease or diseases are 
most responsible or the most important for the pathological process and should be treated 
most intensively. In the light of this kaleidoscope of diagnosis it is easier to understand why 
RCTs so far have been unable to find a single evidence-based therapy for HFpEF. Perhaps a 
more thourough matching for different comorbidities in this population would help to identify 
target groups for specific treatments.  
 
Comorbidity and risk factors 
A common finding in the first three studies is the large frequency and possible importance of 
comorbidities. These comorbidities are important diseases that all may interfere with the 
pathophysiology of HFpEF and we have found that they all in different ways have their own 
association with morbidity and mortality. Various mechanisms are likely for this interference, 
the comorbidity itself may lead to extended stress on a failing heart, as in the case of DM and 
COPD, but may also contribute to missing diagnosis as the symptoms of, for example COPD, 
may resemble those of HF and prevent further investigations. Advanced malignant tumors 
have also potential to stress the failing heart but are reasonably not likely to lead to 
underdiagnosis. It is a well established insight that managing HF patients requires careful 
monitoring of all other factors, and maybe the burden of comorbidities must be correlated to 
the fragility of HF patients where one more disease is actually one to many. Especially in the 
group with EF≥50% among women we have seen that more than half of the deaths are caused 
by other factors than cardiovascular diseases. Given the complexity of the HFpEF group with 
elderly patients in PC it is also understandable that the risk factors for worse prognosis were 
different from patients with HFpEF managed in HC. Besides this, it must be kept in mind that 
SwedeHF only contains information about six other comorbidities whereas a GP every year 
handles hundreds of other diagnoses, many of which probably also may affect HFpEF 
patients.  Treating HFpEF constitutes a major problem, numerous randomized trials have not 
been able to convincingly produce evidence for effective treatments. In light of this, and the 
insights that comorbidities play a central roll for the prognosis in PC, diagnosing and treating 
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these comorbidities stands out as a major task when managing HFpEF patients. This is an 
even more challenging mission since these comorbidities often interact and affects their 
various treatments. In our study we also found a different pattern in HC patients, where there 
was more use of RAS- and betablockade, perhaps reflecting a more severe form of disease in 
HC or the fact that PC physicians, with all other diagnosis to attend to, sometimes may miss 
to fully initiate this medication. Interestingly though, many of these patients should not be 
treated with these substances for their HFpEF according to guidelines but it may be that they 
suffer from other diseases that requires the therapy. It is important to be aware of that we, to 
some extent, are a bit spoiled by the fact that patients with HFrEF have an evidence-based 
treatment including RAS-antagonists and BBs, which work very well in most patients. 
However, patients with HFpEF in PC have a very different etiology of their HF, and therefore 
they require another diagnostic and treatment approch. 
 
The prognostic value of NT-proBNP 
The use of NT-pro BNP is well established as a rule-out tool when diagnosing HF but its 
prognostic significance for HFpEF patients in PC has not been described until now 
previously. We found that there is a statistically significant association between high NT-
proBNP levels and all-cause mortality on a group level. However, due to high standard 
deviations, the clinical usefulness seems limited. The single patient in a GPs office with a 
certain NT-proBNP value may have either a bad or a good prognosis, measuring this will not 
help us. Instead, carefully diagnosing and managing risk factors and comorbidities is possible 
to perform and will actively influence the patients prognosis. 
 
Gender perspectives 
We found in our study significant differences between men and women with HFpEF, both 
when it comes to age, prognosis and morbidity. This is in line with previous studies, but these 
studies have mainly been performed on patients managed in HC. The differences between the 
sexes were most pronounced in the group with EF≥50% where women have a more varied 
pattern of causes of death, perhaps reflecting partly different types of disease. We showed 
that men have a higher age-adjusted mortality. Men are also more often smokers and have 
more IHD, factors that may, at lest partly, explain the higher mortality. Women further have 
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Numerous studies before have shown diagnostic difficulties for HFpEF in PC, and that 
adherence to guidelines is limited. Following these guidelines would otherwise help the 
clinician to properly diagnose not only HF itself but also the type of HF. This, in turn, is 
essential as wrong diagnosis may lead to potentially harmful wrong treatment and further a 
lack of knowledge and research upon HFpEF. As mentioned above, in our study we have not 
been able to thoroughly identify whether the patients in SwedeHF classified as HFpEF have 
all the diagnosric criteria that are required and the diagnose is based on clinical judgement 
and a preserved EF. This is partly understandable since the patients were prospectively 
registered from 2001, when the criterias were different, but may also signify, to some extent 
wrong diagnosis. We have found in our studies a one-year mortality of approximately 7% but 
since only around 55% die from cardiovascular diseases there is a possibility that the other 
45% have another disease, more important than the heart function. If so, one-year mortality 
for those with a more reliable diagnose of HFpEF would be only around 4%. Compared to 
normal one-year mortality for people of this age this is not a high figure which may lead to 
the perception that this is not a fatal disease but it must be kept in mind that the effects on 
quality of life and morbidity of HFpEF is substantial. 
Our fourth study, performed under nowadays conditions, indicate though that there is still 
room for improvement of the diagnostics. An alternative way to help the clinician to pay 
attention to the condition could be to encourage the patients to address the question of 
HFpEF, being alerted via a self-test on the internet. 
 
Limitations 
The SwedeHF is one of the largest HF registries in the world. However, participating in the 
registry is not mandatory in Sweden. Therefore, there is a risk that PC units reporting to the 
registry are more interested in HF and more dedicated to managing HF patients and 
following the current guidelines, potentially leading to a selection of PC units not being 
representative of Swedish PC in general. Possibly the PC cohort in the present study might 
show better results than a study of PC units, in general, would do. 
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Another circumstance of importance, mentioned above, is that the registry does not provide 
information on all possible comorbidities that may influence outcome and prognosis. 
Further, as commented under Diagnostics, is that we have no information on whether 
the diagnosis of HFpEF has been thoroughly established according to the ESC 
classification. This is a clear limitation, as well as the fact that we do not know exactly 
when in the clinical course the NT-proBNP values was examined. However, we know that 
samples most often, according to local routines, are taken in conjunction with the visit. 
 
1.6 CONCLUSIONS 
HFpEF- patients managed in PC, are characterized by higher age, higher proportion of 
women and more patients with EF≥50% than patients managed in HC. Study I 
 Mortality for HFpEF patients in PC is not higher than for out-patients in HC. In total, 97% of 
the patients have more than one disease. Various comorbidities and other factors contribute to 
mortality and must be treated carefully. Study I 
An increased NT-proBNP level is associated with increased all-cause mortality in HFpEF-
patients. However, its clinical usefulness to diagnose or rule out a poor prognosis on 
individual base is limited due to high SDs and the fact that NT-proBNP is not independent in 
this population which is characterized by large heterogeneity, many comorbidities and high 
age. Study II 
Men with HFpEF managed in PC have more IHD, AF and diabetes whereas women have 
more HT and kidney dysfunction. Men have higher age-adjusted mortality, but women have 
worse functional capacity. Study III 
Cardiovascular diseases are the dominating causes of death among both women and men but 
more than a third of the deaths are caused by other diseases where respiratory diseases and 
malignant tumors dominate. In the group with women with EF≥50% this was even more 
pronounced with more than half of the deaths caused by non-cardiovascular diseases. 
Altogether 13 different causes of death were noted.  This illustrates the complexity of this 
group of HF patients and the need to carefully diagnose and treat all associated comorbidities. 
Study III 
We found a potential underdiagnosis of HF in 21% of the studied patients. All these patients 






An on-line self-test for HF may help patients to pay attention to the disease and thus help the 
clinician. Evaluation of such a test to diagnose HF showed an acceptable sensitivity (80 %) to 
find HF and a high negative predictive value of 93 % to rule out the diagnose. The sensitivity 
and negative predictive values were equal to those of the combined use of ECG and NT-
proBNP to diagnose new onset of HF. Study IV 
 
1.6.1 Future perspectives 
 
A common group of patients, from a GPs point of view, is the elderly women with many 
comorbidities, seeking for tiredness and lack of strength. Many of these women may well 
have HFPEF. In the light of the knowledge, from this thesis, upon the complexity of this 
group, with its broad spectrum of comorbidities and different causes of death, future research 
on diagnostics and treatment is important. The results of this thesis indicate that treatment of 
HFpEF-patients should focus more on concomitant diseases and medical history, for example 
CV-diseases and HFpEF, COPD and HFpEF, malignant tumors and HFpEF and so on. Such 
an approach would probably lead to a more individualized management. 
Forthcoming research should further focus on the combination of COPD and HFpEF among 
both men and women as well as the effects of anemia and kidney dysfunction on HFpEF 
patients. This area was only partly studied in this thesis but is of vital importance in this 
elderly population. 
 
Of great interest would also be to more in detail study the group of patients that die from 
another cause of death than cardiovascular diseases and to cooperate with resarchers in other 
fields, such as oncology, to deeper analyze the potential of missing HFpEF and treatment 
possibilities. 
 




Hjärtsvikt med bevarad ejektionsfraktion (HFpEF) är ett sjukdomstillstånd associerat med låg 
livskvalitet, hög sjuklighet och dödlighet. Tillståndet utgör en diagnostisk utmaning och det 
finns ingen vetenskapligt bevisad effektiv behandling. Trots hög prevalens och det faktum att 
många (17-36%) av dessa patienter sköts i primärvården (PV) har de flesta studier utförts i 
sjukhusmiljö (SV). 
Syfte 
Syftet med denna avhandling är att beskriva HFpEF i PV, karakteristika, betydelsen av andra 
samtidigt pågående sjukdomar och dödlighet. Vidare att belysa prognostiska och diagnostiska 
svårigheter samt potentiell underdiagnostik. 
Metod 
De första tre studierna baseras på det svenska hjärtsvikts-kvalitetsregistret Rikssvikt. 
Patienter som saknade ekokardiografisk undersökning (16%) exkluderades. Totalt studerades 
1802 patienter från PV och 7852 från SV, alla med en ejektionsfraktion ≥ 40% med avseende 
på samsjuklighet, riskfaktorer och förlopp. PV jämfördes med SV i den första studien.  
I den andra studien analyserades den prognostiska betydelsen samt värdet av att mäta N-
terminal Brain Natriuretic Peptide (NT-proBNP) hos HFpEF patienter i PV. 924 patienter; 
360 med EF 40-49%, Heart Failure with Midrange Ejection Fraction, (HFmrEF) och 564 
patienter med EF≥50% (HFpEF). 
Den tredje studien analyserade könsskillnader och baserades på de 1802 patienterna i studie I, 
uppdelade på HFmrEF och HFpEF. 
Den fjärde studien utfördes på Gustavsbergs VC. 96 patienter som sökt vårdcentralen under 
en tremånads-period för ett vanligt hjärtsviktssymptom som andfåddhet, bensvullnad eller 
trötthet inkluderades för att identifiera eventuell underdiagnostik samt för att evaluera ett 
internet-baserat självtest för hjärtsviktsdiagnostik. 
Resultat 
HFpEF-patienter I PV var äldre med en större andel kvinnor jämfört med SV. Endast 2.8% 
hade ingen samsjuklighet alls och 1-årsmortaliteten var 7.8%. Rökning, KOL, diabetes 
mellitus, ålder och hjärtfrekvens befanns vara oberoende riskfaktorer för ökad mortalitet i 
PV. Ekokardiografiska undersökningar saknas ofta. I en matchad kontrollgrupp förskrevs mer 
RAS- och betablockad I SV jämfört med PV.  Studie I. 
Det fanns en klar association mellan NT-proBNP-nivåer och mortalitet men bara på 
gruppnivå. Ett flertal variabler var associerade med ökade nivåer av NT-proBNP och även 
oberoende med ökad mortalitet. Studie II. 
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Män hade högre ålders-justerad mortalitet än kvinnor. Hos kvinnor med HFpEF hade över 
hälften en annan dödsorsak än kardiovaskulära sjukdomar. De dominerande andra 
dödsorsakerna var maligniteter och lungsjukdomar men totalt identifierades 13 andra döds-
orsaker. Studie III. 
Vi fann en underdiagnostik av hjärtsvikt ise kommentar ovan, 21% .samtliga kvinnor. Vi fann 
även en acceptabel tillförlitlighet för det internet-baserade hjärtsviktssjälvtestet. Studie IV. 
Slutsats 
Patienter med HFpEF i PV utgör en heterogen grupp med hög ålder och många andra 
sjukdomar som kan påverka hjärtsviktsförloppet men också, oberoende och var för sig, är 
associerade med sjuklighet och dödlighet. Patienterna är äldre (medelålder 78 år) och andelen 
kvinnor är högre (46.7% vs 36.3 %) jämfört med de som sköts inom SV. Det finns ingen 
vetenskapligt dokumenterad behandling som fungerar för hela gruppen.                      
Resultaten i denna avhandling talar för att HFpEF-patienter inom PV har en åldersrelaterad 
multi-organ skada vilket ställer krav på noggrann diagnostik och ett individualiserat 
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